TaBriX has recently received a Proof-of-Principle award from the University of Manchester Innovation Factory to support the completion of the lead optimisation programme of TaBriX assets.
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX’s initial focus is on the treatment of drug-resistant TB. The team has developed a series… Read More »TaBriX and UoM working with TB Alliance to develop novel drugs to treat drug-resistant tuberculosis
The World Health Organisation has released their 2021 Global TB Report. According to the WHO’s website: “Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and… Read More »WHO releases 2021 global TB report
Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals. The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.… Read More »Scientists develop a new drug treatment for tb
Researchers at The University of Manchester are developing a new drug against tuberculosis (TB), one of the oldest human infectious diseases, which is now threatening to reach epidemic proportions once more. TB poses a serious threat to all nations with… Read More »new drug to stop tuberculosis epidemic